Interestingly, a subgroup of patients with high FEV1 reversibility at inclusion demonstrated a significant difference in asthma control, suggesting that patients with not-yet-established permanent obstruction and airway remodeling might benefit from IL-17 blockade strategy in the early phase of airway remodeling (206, 209, 210). Here, IL17A is linked to asthma.